POLISCOPE
Back to feed
NewsFOX 13 Tampa BayAugust 19, 2026Hillsborough

Moderna and Merck report successful late-stage trial for personalized mRNA melanoma vaccine

Moderna announced that its personalized mRNA cancer vaccine, when used alongside the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or spread in a late-stage clinical trial. The companies are now preparing for potential regulatory approval, with the vaccine potentially available to high-risk patients as early as next year.

healthcarebiotechnologycancer researchpharmaceuticalsinvesting
Read the full story at FOX 13 Tampa Bay

Why It Matters

This development represents the first successful for an cancer vaccine, potentially offering a new treatment option for thousands of patients with high-risk melanoma.

Key Facts

  • The mRNA vaccine is designed to train the immune system to recognize and attack specific mutations in cancer cells.
  • The trial results showed a reduction in the risk of melanoma returning or spreading when the vaccine was combined with Keytruda.
  • Moderna's market value increased by nearly $40 billion following the announcement.
  • Merck's share price rose 11% following the trial results.
  • The Nasdaq Biotechnology Index reached a record high, rising 4.4%.
  • The vaccine is personalized for each patient, which may present challenges for large-scale production.
  • Moderna and Merck have not yet determined the cost of the treatment.
  • More than 1.5 million people in the U.S. were living with melanoma in 2023.
  • Similar mRNA vaccine studies are currently underway for lung, breast, and pancreatic cancers.

Who's Mentioned

organizationModerna“Developer of the mRNA cancer vaccine”personStephane Bancel“CEO of Moderna”organizationMerck“Partner in vaccine development and manufacturer of Keytruda”personStephen Hoge“President of Moderna”personKaren Knudsen“CEO of the Parker Institute for Cancer Immunotherapy”